The Buck Institute for Research on Aging, Insilico Medicine and Juvenescence have joined together to form a fourth company, Napa Therapeutics. Napa will develop anti-aging drugs against a NAD+ target discovered in the labs of Eric Verdin, President and CEO of the Buck Institute, an independent research center located in Novato, CA. Insilico is a company that uses AI to develop better drugs more quickly. In June, it announced a funding round led by WuXi AppTec. Insilico could earn more than $100 million in milestone payments from Napaif the program is successful.
Source: China Biotoday
